Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Pharmacogenomics Market Outlook 2026-2035 - Featuring Profiles of Thermo Fisher Scientific, Illumina, and Qiagen

globenewswire.com
TMO Thermo Fisher Scientific is mentioned as a major company operating in the growing global pharmacogenomics market, which is projected to reach USD 15.4 billion by 2035. The article highlights the company's participation in technological innovation and expansion of precision medicine portfolios. ILMN Illumina is listed as a key player in the expanding pharmacogenomics market. The company is expected to benefit from advancements in next-generation sequencing and the increasing adoption of precision diagnostics, contributing to the market's projected growth to USD 15.4 billion by 2035. QGEN Qiagen is identified as a major company in the pharmacogenomics market, which is forecast to grow significantly. The article notes the company's involvement in technological innovation and expansion of precision medicine portfolios within this expanding sector. DHR Danaher Corporation is mentioned as a major company operating in the global pharmacogenomics market. The article indicates the market's significant growth potential, with Danaher positioned to benefit from advancements in genomic technologies and precision medicine. BDX Becton, Dickinson and Company (BD) is named as a key player in the pharmacogenomics market. The article highlights the market's growth drivers, including advancements in genomic technologies and precision diagnostics, in which BD is involved. BIO Bio-Rad Laboratories is mentioned as a major company in the pharmacogenomics market, which is expected to see significant expansion. The company's role in technological innovation and precision medicine portfolios positions it within this growing sector.

Pharmacogenomics Market Outlook 2026-2035 - Featuring Profiles of Thermo Fisher Scientific, Illumina, and Qiagen Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Pharmacogenomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.

Global Pharmacogenomics Market to Reach USD 15.4 Billion by 2035, Driven by Precision Medicine Adoption

The global pharmacogenomics market was valued at USD 5.7 billion in 2025 and is projected to reach USD 15.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 10.6% during the forecast period.

Market growth is being driven by the increasing integration of genomic data into clinical decision-making, rising adoption of precision diagnostics, and wider availability of multi-gene testing technologies. Continued advances in next-generation sequencing, PCR-based testing, microarrays, bioinformatics platforms, companion diagnostics, and laboratory automation are improving the accessibility and clinical value of pharmacogenomic testing.

Declining sequencing costs, supportive regulatory developments, and greater awareness of genetics-guided prescribing are also accelerating adoption. Hospitals, pharmaceutical companies, research institutions, diagnostic laboratories, and other healthcare organizations are using pharmacogenomic information to improve treatment outcomes, optimize drug selection, reduce medication-related risks, and support more efficient use of healthcare resources.

Product Segment Maintains Leading Market Share

The products segment accounted for 67% of the global pharmacogenomics market in 2025 and is forecast to grow at a CAGR of 10.5% through 2035. The segment includes next-generation sequencing systems, PCR-based products, microarray technologies, sample preparation tools, bioinformatics platforms, companion diagnostic solutions, and laboratory automation equipment.

Demand for advanced genetic analysis capabilities and scalable precision medicine workflows continues to support product adoption. Ongoing investment in testing accuracy, sequencing capacity, data interpretation, and clinical integration is expected to create further opportunities for technology developers and diagnostic solution providers.

Hospitals and Clinics Expand Pharmacogenomic Testing

The hospitals and clinics segment held a 37.9% market share in 2025 and is projected to expand at a CAGR of 10.4% through 2035. Healthcare institutions, specialty care facilities, and physician practices are increasingly incorporating pharmacogenomic testing into patient management and treatment planning.

Greater clinical awareness, growing demand for optimized drug selection, and the rising priority placed on reducing adverse medication outcomes are strengthening adoption across healthcare environments. Broader integration into routine clinical workflows is expected to support sustained segment growth throughout the forecast period.

North America Leads the Global Pharmacogenomics Market

North America represented 48.4% of global market revenue in 2025 and is anticipated to grow at a CAGR of 10.4% through 2035. The region's leadership is supported by advanced healthcare infrastructure, established genomic research capabilities, favorable regulatory frameworks, and strong adoption of precision medicine.

The United States remains the principal contributor to regional growth. Expanding clinical implementation, increased investment in genomic technologies, and the integration of genetic information into healthcare decision-making are reinforcing the country's market position. Continued development of precision healthcare systems is expected to preserve North America's leading share.

Competitive Landscape and Company Strategies

Major companies operating in the global pharmacogenomics market include Illumina, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Qiagen, Danaher Corporation, Agilent Technologies, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Charles River Laboratories, Eurofins Scientific, LabCorp, Revvity, Novogene Co., Ltd., Takara Bio Inc., Genomind, OneOme, Genelex, and Admera Health.

Market participants are prioritizing technological innovation, strategic partnerships, research and development, and the expansion of precision medicine portfolios. Competitive strategies include improving genetic testing accuracy, advancing sequencing systems, strengthening bioinformatics capabilities, and developing customized diagnostic services. Collaborations among pharmaceutical companies, healthcare providers, diagnostic laboratories, and research institutions are helping accelerate commercialization and broaden clinical adoption.

Companies are also investing in regulatory compliance, scalable laboratory infrastructure, digital health integration, and automated data analysis. These initiatives are expected to strengthen competitive positioning while addressing rising demand for clinically actionable genomic information.

Comprehensive Pharmacogenomics Market Analysis and Forecast

The global pharmacogenomics market is positioned for sustained expansion as genetic testing becomes more closely integrated with drug development and patient care. Continuous innovation, greater clinical accessibility, and growing investment in genomic infrastructure are expected to support long-term market growth through 2035.

Key Attributes:

Key Topics Covered:

Chapter 1 Methodology & Scope

1.1 Research approach

1.2 Quality commitments

1.2.1 GMI AI policy & data integrity commitment

1.2.1.1 Source consistency protocol

1.3 Research trail & confidence scoring

1.3.1 Research trail components

1.3.2 Scoring components

1.4 Data collection

1.4.1 Partial list of primary sources

1.5 Data mining sources

1.5.1 Paid sources

1.5.1.1 Sources, by region

1.6 Base estimates and calculations

1.6.1 Base year calculation for any one approach

1.7 Market estimates & forecasts parameters

1.8 Forecast model

1.8.1 Quantified market impact analysis

1.8.1.1 Mathematical impact of growth parameters on forecast

1.9 Research transparency addendum

1.9.1 Source attribution framework

1.9.2 Quality assurance metrics

1.9.3 Our commitment to trust

Chapter 2 Executive Summary

2.1 Industry 360 synopsis

2.1.1 Business trends

2.1.2 Offering trends

2.1.3 Technology trends

2.1.4 Application trends

2.1.5 Disease area trends

2.1.6 End use trends

2.1.7 Regional trends

2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Increasing demand for precision medicine

3.2.1.2 Rising burden of adverse drug reactions

3.2.1.3 Advancements in genomic technologies

3.2.1.4 Increasing prevalence of chronic diseases

3.2.1.5 Increasing adoption of pharmacogenomics in drug development and clinical workflows

3.2.2 Industry pitfalls and challenges

3.2.2.1 Cost and reimbursement challenges

3.2.2.2 Complexity and interpretation of genetic data

3.2.3 Market opportunities

3.2.3.1 Innovation in microbiome-based and hormone-targeted therapies

3.2.3.2 Development of multi-gene panels and companion diagnostics

3.3 Growth potential analysis

3.4 Technology and innovation landscape

3.4.1 Current technological trends

3.4.2 Emerging technologies

3.5 Regulatory landscape (Driven by primary research)

3.5.1 North America

3.5.2 Europe

3.5.3 Asia-Pacific

3.5.4 Latin America

3.5.5 MEA

3.6 Porter's analysis

3.7 PESTEL analysis

3.8 Future market trends

3.9 Impact of AI and Generative AI on the market (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

4.1 Introduction

4.2 Company market share analysis

4.2.1 North America

4.2.2 Europe

4.2.3 Asia-Pacific

4.3 Company matrix analysis

4.4 Competitive analysis of major market players

4.5 Competitive positioning matrix

4.6 Key developments

4.6.1 Merger and acquisition

4.6.2 Partnership and collaboration

4.6.3 New product launches

4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, by Offering, 2022-2035 ($ Mn)

5.1 Key trends

5.2 Products

5.2.1 Kits and reagents

5.2.2 Instruments

5.3 Services

Chapter 6 Market Estimates and Forecast, by Technology, 2022-2035 ($ Mn)

6.1 Key trends

6.2 Sequencing

6.3 PCR

6.4 Microarray

6.5 Other technologies

Chapter 7 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)

7.1 Key trends

7.2 Personalized medicine

7.3 Clinical research

7.4 Drug discovery and preclinical development

7.5 Other applications

Chapter 8 Market Estimates and Forecast, by Disease Area, 2022-2035 ($ Mn)

8.1 Key trends

8.2 Oncology

8.3 Cardiovascular diseases

8.4 Neurological diseases

8.5 Infectious diseases

8.6 Mental health

8.7 Other disease areas

Chapter 9 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)

9.1 Key trends

9.2 Hospitals and clinics

9.3 Academic and research institutions

9.4 Pharmaceutical and biotechnology companies

9.5 Contract research organizations (CROs)

9.6 Other end users

Chapter 10 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)

10.1 Key trends

10.2 North America

10.2.1 U.S.

10.2.2 Canada

10.3 Europe

10.3.1 Germany

10.3.2 France

10.3.3 UK

10.3.4 Spain

10.3.5 Italy

10.3.6 Netherlands

10.4 Asia-Pacific

10.4.1 China

10.4.2 Japan

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.5 Latin America

10.5.1 Brazil

10.5.2 Mexico

10.5.3 Argentina

10.6 Middle East & Africa

10.6.1 Saudi Arabia

10.6.2 South Africa

10.6.3 UAE

Chapter 11 Company Profiles

11.1 Admera Health

11.2 Agilent Technologies Inc.

11.3 Becton, Dickinson and Company

11.4 Bio-Rad Laboratories Inc.

11.5 Charles River Laboratories

11.6 Danaher Corporation

11.7 Eurofins Scientific

11.8 F. Hoffmann-La Roche Ltd.

11.9 Genelex

11.10 Genomind

11.11 Illumina Inc.

11.12 Labcorp Holdings Inc.

11.13 Novogene Co., Ltd.

11.14 OneOme

11.15 Qiagen N.V.

11.16 Revvity

11.17 Takara Bio Inc.

11.18 Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/10hlxp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.